|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TAB 2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
International multicenter clinical study - The use
of preparations containing glycyrhizinic acid |
|
|
|
in dermatology practice - Survey of basic patients
data - group Herpes simplex |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Num |
Herpes simplex |
Men |
ø Age |
Women |
ø Age |
A |
B |
C |
D |
DE |
DT |
PE |
PT |
E |
|
|
1 |
auriculae |
L.K. |
12 |
- |
- |
5 |
4 |
0 |
0 |
1 |
1 |
1 |
2 |
0 |
|
|
2 |
labii oris |
- |
- |
E.K. |
34 |
5 |
4 |
0 |
0 |
1 |
1 |
1 |
1 |
0 |
|
|
3 |
labii oris |
- |
- |
A.L. |
32 |
5 |
5 |
0 |
0 |
2 |
1 |
2 |
1 |
0 |
|
|
4 |
labii oris |
- |
- |
E.Ž. |
63 |
5 |
4 |
0 |
0 |
3 |
2 |
2 |
2 |
0 |
|
|
5 |
labii oris |
- |
- |
E.Š |
46 |
4 |
4 |
0 |
0 |
2 |
2 |
1 |
1 |
0 |
|
|
6 |
glutealis |
P.J. |
70 |
- |
- |
4 |
30 |
0 |
0 |
1 |
1 |
1 |
1 |
0 |
|
|
7 |
labii oris |
- |
- |
S.V. |
78 |
4 |
18 |
0 |
0 |
1 |
1 |
1 |
1 |
0 |
|
|
8 |
labii oris |
- |
- |
S.M. |
52 |
4 |
60 |
0 |
0 |
2 |
2 |
2 |
2 |
0 |
|
|
9 |
labii oris |
- |
- |
Š.I. |
25 |
4 |
30 |
0 |
0 |
3 |
3 |
3 |
3 |
0 |
|
|
10 |
glutealis |
- |
- |
S.D. |
24 |
4 |
30 |
0 |
0 |
3 |
3 |
3 |
3 |
0 |
|
|
11 |
labii oris |
|
- |
P.M. |
41 |
5 |
5 |
0 |
0 |
1 |
1 |
1 |
1 |
0 |
|
|
12 |
labii oris |
S.L. |
20 |
- |
- |
5 |
4 |
0 |
0 |
1 |
1 |
1 |
1 |
0 |
|
|
13 |
labii oris |
- |
- |
V.M. |
59 |
5 |
5 |
0 |
0 |
1 |
1 |
1 |
1 |
0 |
|
|
14 |
labii oris |
- |
- |
P.M. |
34 |
5 |
4 |
0 |
0 |
1 |
1 |
1 |
1 |
0 |
|
|
15 |
labii oris |
H.M. |
26 |
- |
- |
4 |
5 |
0 |
0 |
1 |
1 |
1 |
1 |
0 |
|
|
16 |
labii oris |
- |
- |
Č.V. |
33 |
4 |
3 |
0 |
0 |
1 |
1 |
1 |
1 |
0 |
|
|
17 |
labii oris |
- |
- |
G.T. |
53 |
5 |
5 |
0 |
0 |
1 |
1 |
1 |
1 |
0 |
|
|
18 |
labii oris |
B.J. |
39 |
|
|
5 |
5 |
0 |
0 |
1 |
1 |
1 |
1 |
0 |
|
|
19 |
labii oris |
- |
- |
P.K. |
29 |
4 |
4 |
0 |
0 |
1 |
1 |
1 |
1 |
0 |
|
|
20 |
labii oris |
P.Z. |
34 |
- |
- |
4 |
4 |
0 |
0 |
1 |
1 |
1 |
1 |
0 |
|
|
21 |
labii oris |
R.P. |
26 |
- |
- |
4 |
5 |
0 |
0 |
1 |
1 |
1 |
1 |
0 |
|
|
22 |
labii oris |
P.M. |
19 |
- |
- |
4 |
5 |
0 |
0 |
1 |
1 |
1 |
1 |
0 |
|
|
23 |
labii oris |
- |
- |
G.L. |
18 |
5 |
5 |
0 |
0 |
1 |
1 |
1 |
1 |
0 |
|
|
24 |
labii oris |
- |
- |
R.L. |
29 |
4 |
3 |
0 |
0 |
1 |
1 |
1 |
1 |
0 |
|
|
Summary |
8 |
30,75 |
16 |
40,63 |
4,46 |
#### |
- |
- |
- |
- |
- |
- |
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Legend |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
A - number of aplication/day |
|
|
|
|
|
|
|
|
|
|
|
|
|
B - duration of aplication/day |
|
|
|
|
|
|
|
|
|
|
|
|
|
C - Undesirable effects |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
D - Relaps |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
DE/DT - evaluation of doctor - effect/tolerance |
|
|
|
|
|
|
|
|
|
|
|
PE/PT- eavaluation of patient - effect/tolerance |
|
|
|
|
|
|
|
|
|
|
E - interruption of application |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effect |
|
|
|
Tolerance |
|
|
|
|
|
|
|
|
|
|
1 - very good |
|
|
|
1- very good |
|
|
|
|
|
|
|
|
|
|
2 - good |
|
|
|
2 - good |
|
|
|
|
|
|
|
|
|
|
3 - no effect |
|
|
|
3 - no effect |
|
|
|
|
|
|
|
|
|
|
4 - degradation |
|
|
|
4 - exacerbation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Graph 3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
International multicenter clinical study - The use
of preparations containing glycyrhizinic acid |
|
|
|
in dermatology practice - Survey of basic patients
data - group Herpes simplex |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Graph 4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
International multicenter clinical study - The use
of preparations containing glycyrhizinic acid |
|
|
|
in dermatology practice - Survey of basic patients
data - group Herpes simplex |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|